Cover Image
市場調查報告書

Hyundai Pharmaceutical Co., Ltd.的產品平台分析

Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 319978
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Hyundai Pharmaceutical Co., Ltd.的產品平台分析 Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016
出版日期: 2016年12月30日 內容資訊: 英文 42 Pages
簡介

Hyundai Pharmaceutical Co., Ltd.是總公司在韓國的製藥企業。製藥產品和保健食品、飲料,進行著醫療設備等的製造、銷售。

本報告提供Hyundai Pharmaceutical Co., Ltd.的治療藥開發平台的現狀及各開發階段比較分析,各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

目錄

Hyundai Pharmaceutical Co., Ltd.的基本資料

  • Hyundai Pharmaceutical Co., Ltd.概要
  • 主要資訊
  • 企業資料

Hyundai Pharmaceutical Co., Ltd.:R&D概要

  • 主要的治療範圍

Hyundai Pharmaceutical Co., Ltd.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Hyundai Pharmaceutical Co., Ltd.:開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Hyundai Pharmaceutical Co., Ltd.:藥物簡介

  • NZ-419
  • choline alfoscerate SR
  • HOB-048
  • HOB-051
  • HD-0471042
  • HD-0471953
  • UHC-1
  • HOB-046
  • HOB-047

Hyundai Pharmaceutical Co., Ltd.:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Hyundai Pharmaceutical Co., Ltd.:開發暫停中的計劃

Hyundai Pharmaceutical Co., Ltd.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08176CDB

Summary

Global Markets Direct's, 'Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016', provides an overview of the Hyundai Pharmaceutical Co Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Hyundai Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Hyundai Pharmaceutical Co Ltd
  • The report provides overview of Hyundai Pharmaceutical Co Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Hyundai Pharmaceutical Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Hyundai Pharmaceutical Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Hyundai Pharmaceutical Co Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyundai Pharmaceutical Co Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyundai Pharmaceutical Co Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyundai Pharmaceutical Co Ltd Snapshot
    • Hyundai Pharmaceutical Co Ltd Overview
    • Key Facts
  • Hyundai Pharmaceutical Co Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Hyundai Pharmaceutical Co Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Hyundai Pharmaceutical Co Ltd - Pipeline Products Glance
    • Hyundai Pharmaceutical Co Ltd - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Hyundai Pharmaceutical Co Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Hyundai Pharmaceutical Co Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Hyundai Pharmaceutical Co Ltd - Drug Profiles
    • BPS-015 SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • choline alfoscerate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-0471042 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-0471953 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-6277 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-060 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-071 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-075 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTB-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTB-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levodropropizine CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tranexamic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UHC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hyundai Pharmaceutical Co Ltd - Pipeline Analysis
    • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Target
    • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Route of Administration
    • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Molecule Type
    • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action
  • Hyundai Pharmaceutical Co Ltd - Dormant Projects
  • Hyundai Pharmaceutical Co Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hyundai Pharmaceutical Co Ltd, Key Facts
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Indication, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016
  • Hyundai Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016
  • Hyundai Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016
  • Hyundai Pharmaceutical Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Hyundai Pharmaceutical Co Ltd - Phase III, 2016
  • Hyundai Pharmaceutical Co Ltd - Phase II, 2016
  • Hyundai Pharmaceutical Co Ltd - Phase I, 2016
  • Hyundai Pharmaceutical Co Ltd - Preclinical, 2016
  • Hyundai Pharmaceutical Co Ltd - Discovery, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Target, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action, 2016
  • Hyundai Pharmaceutical Co Ltd - Dormant Developmental Projects,2016

List of Figures

  • Hyundai Pharmaceutical Co Ltd - Pipeline by Top 10 Indication, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016
  • Hyundai Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016
  • Hyundai Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Top 10 Target, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016
  • Hyundai Pharmaceutical Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top